- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| SCIBASE Aktie jetzt für 0€ handeln | |||||
| Mo | SciBase resolves on a directed share issue of approximately SEK 11 million | 214 | PR Newswire | STOCKHOLM, June 23, 2025 /PRNewswire/ -- The board of directors of SciBase Holding AB (publ) ("SciBase" or the "Company") has today, in accordance with the intention published by the Company... ► Artikel lesen | |
| 17.06. | Bulletin from the annual general meeting in SciBase Holding AB (publ) | 350 | PR Newswire | STOCKHOLM, June 17, 2025 /PRNewswire/ -- Today, the annual general meeting 2025 has been held in SciBase Holding AB (publ) ("SciBase" or the "Company"). The general meeting resolved in accordance... ► Artikel lesen | |
| 17.06. | SciBase has signed a Collaboration and License Agreement with Castle Biosciences to develop diagnostic tests within dermatology and intends to carry out a directed share issue of approximately MSEK 30 | 236 | PR Newswire | STOCKHOLM, June 17, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of AI-based diagnostic solutions for skin disorders, today announced it has signed... ► Artikel lesen | |
| 16.06. | Castle Biosciences partners with SciBase for diagnostic tests | 1 | Seeking Alpha | ||
| 16.06. | SciBase resolves on a directed share issue of SEK 19 million and announces its intention to carry out an additional directed share issue of approximately SEK 11 million | 307 | PR Newswire | STOCKHOLM, June 16, 2025 /PRNewswire/ -- The board of directors of SciBase Holding AB (publ) ("SciBase" or the "Company") has today, pursuant to the authorisation granted by the annual general... ► Artikel lesen | |
| 16.06. | Castle Biosciences partners with SciBase to develop atopic dermatitis test | 1 | Investing.com | ||
| 16.06. | Castle Biosciences, Inc.: Castle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases | 80 | GlobeNewswire (Europe) | FRIENDSWOOD, Texas, June 16, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it... ► Artikel lesen | |
| 09.06. | SciBase Initiates Self-Pay Model in the US to Make Nevisense Test More Accessible to Patients | 227 | PR Newswire | STOCKHOLM, June 9, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders, today announced the launch... ► Artikel lesen | |
| 04.06. | SciBase Expands Further Through European Market with First Sales Order to customer in Italy | 206 | PR Newswire | STOCKHOLM, June 4, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders, today announced its first... ► Artikel lesen | |
| 27.05. | SciBase reaches milestone with over 300,000 patients tested with Nevisense | 224 | PR Newswire | STOCKHOLM, May 27, 2025 /PRNewswire/ -- SciBase Holding AB ('SciBase') (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders, today announced a major... ► Artikel lesen | |
| 23.05. | SciBase publishes the Annual report for 2024 | 238 | PR Newswire | STOCKHOLM, May 23, 2025 /PRNewswire/ -- SciBase hereby announces that the Annual report for 2024 is available at the Company's website www.scibase.com.
A pdf-version of the annual report... ► Artikel lesen | |
| 14.05. | Notice to attend the annual general meeting in Scibase Holding AB (publ) | 230 | PR Newswire | STOCKHOLM, May 14, 2025 /PRNewswire/ -- Shareholders of SciBase Holding AB (publ), reg. no. 556773-4768 (the "Company"), are hereby summoned to the annual general meeting to be held on 17... ► Artikel lesen | |
| 13.05. | SciBase: Interim report | 220 | PR Newswire | STOCKHOLM, May 13, 2025 /PRNewswire/ --
January 1 - March 31, 2025
The first quarter in figures
Net sales were TSEK 8,856 (6,057), +46%. The loss after tax was TSEK 27,510... ► Artikel lesen | |
| 11.04. | SciBase launches next generation Nevisense | 242 | PR Newswire | STOCKHOLM, April 11, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders, is proud to announce... ► Artikel lesen | |
| 25.02. | Year-end report: SciBase | 301 | PR Newswire | STOCKHOLM, Feb. 25, 2025 /PRNewswire/ --
January 1 - December 30, 2024
The fourth quarter in figures
Net sales were TSEK 8,598 (5,764), +49%.The loss after tax was TSEK 17... ► Artikel lesen | |
| 25.02. | SCIBASE: Year-end report | 5 | Cision News | ||
| 21.02. | SciBase: New study shows significant improved clinical accuracy with Nevisense for both US and German dermatologists | 295 | PR Newswire | STOCKHOLM, Feb. 21, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders announced today, that... ► Artikel lesen | |
| 30.01. | SciBase continues US expansion, on-boards Several US Dermatology Practices that Specialize in Skin Cancer Detection | 239 | PR Newswire | STOCKHOLM, Jan. 30, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders announced today that... ► Artikel lesen | |
| 28.01. | SciBase: New review article highlights Nevisense effectiveness in identifying malignant skin lesions | 282 | PR Newswire | STOCKHOLM, Jan. 28, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders announced today that... ► Artikel lesen | |
| 27.01. | SciBase: Recalculation of warrants of series TO 2 following rights issue | 385 | PR Newswire | STOCKHOLM, Jan. 27, 2025 /PRNewswire/ -- In accordance with the terms and conditions for warrants of series TO 2, which were issued in connection with the capital raise announced in April... ► Artikel lesen |
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ROKU | 73,28 | -1,32 % | Should You Buy Roku Stock After Its Partnership With Amazon? | ||
| SERNOVA BIOTHERAPEUTICS | 0,109 | +3,81 % | Sernova Biotherapeutics, Inc.: Sernova Appoints Jonathan Rigby as Interim Chair | LONDON, Ontario and BOSTON, June 02, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing its... ► Artikel lesen | |
| BOSTON SCIENTIFIC | 90,80 | -0,44 % | Do You Believe in the Growth Trajectory of Boston Scientific Corporation (BSX)? | ||
| PAUL HARTMANN | 245,00 | +0,82 % | Dividendenbekanntmachungen (02.05.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADECOAGRO SA LU0584671464 0,175 USD 0,155 EUR AKER ASA NO0010234552 26,5 NOK 2,2495 EUR ALIMAK GROUP AB SE0007158910 3 SEK 0... ► Artikel lesen | |
| SYSMEX | 14,900 | +0,68 % | Macrium Software: Macrium Partners with Sysmex America to Reduce Medical Testing Downtime and Improve Patient Care | British-based backup and recovery technology reduces labour costs by up to 75% while minimising downtime, creating a win-win for healthcare providers and patients.
MANCHESTER, England... ► Artikel lesen | |
| ADDLIFE | 16,400 | -1,68 % | Dividendenbekanntmachungen (09.05.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AAK AB SE0011337708 5 SEK 0,4573 EUR ADDLIFE AB SE0014401378 0,75 SEK 0,0686 EUR ALLIANZ SE DE0008404005 - 15,4 EUR ALZCHEM GROUP... ► Artikel lesen | |
| EMBECTA | 8,050 | -2,42 % | Dividendenbekanntmachungen (28.05.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABO ENERGY GMBH & CO KGAA DE0005760029 - 0,65 EUR AIA GROUP LTD HK0000069689 1,3098 HKD 0,1474 EUR ALLIANZ SE ADR US0188201000 1... ► Artikel lesen | |
| ENOVIS | 28,000 | +2,94 % | Enovis Corporation: Enovis Announces First Quarter 2025 Results | Continued commercial momentum with first-quarter sales growth of 8% on a reported basis and strong adjusted EBITDA margin expansion First-quarter Reconstructive sales grew 11% year-over-year on a reported... ► Artikel lesen | |
| R1 RCM | 13,400 | 0,00 % | R1 RCM Inc. (RCM): Driving Strong Revenue Growth with AI-Driven Solutions and Strategic Partnerships in Healthcare | ||
| KANGJI MEDICAL | 0,840 | +3,70 % | KANGJI MEDICAL (09997): DIVIDEND CURRENCY ELECTION FORM FOR THE FINAL DIVIDEND FOR THE YEAR ENDED DECEMBER 31, 2024 | ||
| PULMONX | 2,140 | -3,60 % | Pulmonx Corporation: Pulmonx Reports Record Fourth Quarter and Full Year 2024 Financial Results | REDWOOD CITY, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported... ► Artikel lesen | |
| SI-BONE | 15,500 | -1,90 % | SI-BONE, Inc. Reports Financial Results for the First Quarter 2025 and Updates 2025 Guidance | First Quarter 2025 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $47.3 million, representing growth of 24.9%U.S. revenue of $44.8 million, representing... ► Artikel lesen | |
| REVITALIST LIFESTYLE AND WELLNESS | 0,015 | -100,00 % | Revitalist Lifestyle & Wellness Ltd: Revitalist Announces Filing of Audited Financial Statements for the Year-Ended December 31, 2022 and Provides Update on Cease Trade Order | Vancouver, British Columbia--(Newsfile Corp. - February 18, 2025) - Revitalist Lifestyle and Wellness Ltd. (CSE: CALM) (OTCQB: RVLWF) (FSE: 4DO) (the "Company") wishes to announce that, further to... ► Artikel lesen | |
| PEIJIA MEDICAL | 0,685 | +0,74 % | Peijia Medical Announces 2024 Annual Results | HONG KONG, March 26, 2025 /PRNewswire/ -- Peijia Medical (9996.HK), a leading Chinese domestic player in the high-growth transcatheter valve therapeutics and... ► Artikel lesen | |
| KOOTH | 2,160 | 0,00 % | Kooth PLC - Result of 2025 Annual General Meeting |
SCIBASE HOLDING AB gehört der Branche Gesundheitswesen an. Der aktuelle Kurs liegt bei 0,009 Euro und damit +9,52 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SCIBASE HOLDING AB finden Sie auf Wallstreet Online.